XSpray Pharma (Sweden) Investor Sentiment

XSPRAY Stock  SEK 42.40  0.45  1.07%   
About 51% of XSpray Pharma's investor base is interested to short. The analysis of current outlook of investing in XSpray Pharma AB suggests that many traders are impartial regarding XSpray Pharma's prospects. The current market sentiment, together with XSpray Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use XSpray Pharma AB stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at news.google.com         
Hancock Whitney Renews Share Repurchase Authorization - Business Wire
Google News at Macroaxis
over two weeks ago at news.google.com         
Xspray Pharma has decided on previously announced rights issue - Marketscreener.com
Google News at Macroaxis
over two weeks ago at news.google.com         
Final outcome in Xspray Pharmas rights issue in line with preliminary announcement - Marketscreener....
Google News at Macroaxis
over two weeks ago at news.google.com         
Xspray Pharma reports minor accounting changes - Marketscreener.com
Google News at Macroaxis
over a month ago at news.google.com         
Xspray Pharma AB s institutional investors lost 19 percent over the past week but have profited from...
Google News at Macroaxis
over two months ago at news.google.com         
Xylem to Release Third Quarter 2024 Financial Results on October 31, 2024 - Business Wire
Google News at Macroaxis
over two months ago at news.google.com         
Analysts Expect Breakeven For Xspray Pharma AB Before Long - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission - StockTitan
Google News at Macroaxis
over three months ago at news.google.com         
Scientific Article in Leading Journal Endorses Xspray Pharmas HyNap Technology - StockTitan
Google News at Macroaxis
over three months ago at news.google.com         
Director of Xspray Pharma Picks Up 14 percent More Stock - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Xspray Pharma needs to provide more info to the FDA - Redeye flags a 20 percent lower valuation rang...
Google News at Macroaxis
over three months ago at news.google.com         
Xspray Pharmas XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50 percent Lower...
Google News at Macroaxis
over three months ago at news.google.com         
Biotech Stocks Facing FDA Decision In July 2024 - Nasdaq
Google News at Macroaxis
over six months ago at news.google.com         
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients ...
Google News at Macroaxis
over six months ago at news.google.com         
Bullish Xspray Pharma Insiders Rewarded As Their Investment Rises To kr11.7m - Simply Wall St
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about XSpray Pharma that are available to investors today. That information is available publicly through XSpray media outlets and privately through word of mouth or via XSpray internal channels. However, regardless of the origin, that massive amount of XSpray data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of XSpray Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of XSpray Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to XSpray Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive XSpray Pharma alpha.

XSpray Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for XSpray Stock analysis

When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments